Alnylam Pharmaceuticals, Inc.
ALNY
$304.67
$6.092.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.21% | 22.97% | 21.54% | 89.46% | 75.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.21% | 22.97% | 21.54% | 89.46% | 75.20% |
| Cost of Revenue | 2.15% | 4.18% | 11.09% | 31.04% | 70.96% |
| Gross Profit | 20.09% | 26.81% | 23.52% | 102.99% | 76.04% |
| SG&A Expenses | 22.11% | 22.61% | 8.72% | 1.41% | 2.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.05% | 14.91% | 9.86% | 8.63% | 12.82% |
| Operating Income | 34.37% | 37.31% | 46.91% | 112.42% | 77.69% |
| Income Before Tax | -9.44% | 12.95% | 36.14% | 94.18% | 69.36% |
| Income Tax Expenses | -1,268.30% | -1,575.36% | 59.11% | 180.81% | 49.16% |
| Earnings from Continuing Operations | 18.78% | 36.82% | 34.83% | 93.14% | 68.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.78% | 36.82% | 34.83% | 93.14% | 68.82% |
| EBIT | 34.37% | 37.31% | 46.91% | 112.42% | 77.69% |
| EBITDA | 52.73% | 47.30% | 55.88% | 120.41% | 83.45% |
| EPS Basic | 21.16% | 38.54% | 36.38% | 93.35% | 69.50% |
| Normalized Basic EPS | -9.88% | 12.84% | 36.72% | 95.65% | 69.00% |
| EPS Diluted | 21.90% | 38.96% | 36.88% | 93.03% | 69.20% |
| Normalized Diluted EPS | -7.18% | 14.43% | 37.70% | 94.86% | 68.22% |
| Average Basic Shares Outstanding | 2.49% | 2.20% | 1.97% | 1.92% | 2.28% |
| Average Diluted Shares Outstanding | 1.25% | 0.96% | 0.74% | 3.16% | 3.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |